ACCC okays Pfizer’s Hospira acquisition

The Australian Competition and Consumer Commission has announced that it will not oppose Pfizer Inc’s proposed $US17 billion acquisition of Hospira Inc. “Pfizer and Hospira are also the two largest suppliers of small molecule drugs in Australia, which are used in hospitals to treat illnesses including cancers, cardiovascular and metabolic diseases, epilepsy, and serious infections,”